CEL-SCI Corporation

CEL-SCI Corporation is a Phase 3 cancer immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. The company is conducting a Phase 3 trial of Multikine (leukocyte interleukin injection) for the treatment of head-and-neck cancer in 17 countries. CEL-SCI is also developing treatments for HIV/HPV coinfected patients with anal warts in collaboration with the U.S. Navy at the San Diego Naval Medical Center through a cooperative research and development agreement. The company operates its own 75,000 sq ft manufacturing facility near Baltimore, MD.

Expert Comments:

Acceleron Equity Research (1/12/15)
"In its Phase 3 trial for the treatment of head-and-neck cancer, the largest Phase 3 study for this indication in the world, CEL-SCI Corporation has executed on rapid acceleration in patient enrollment. The company reported an eight-fold increase in patient enrollment in 2014 over 2013 levels. Given the 800% increase in annual enrollment between 2013 and 2104, we assume CEL-SCI will comfortably complete enrollment in 2015."

Edward White, Laidlaw & Company (11/3/14)
"CEL-SCI Corporation announced the pricing of a secondary public offering and a registered direct offering for combined gross proceeds of approximately $7M. . .following the offering, we estimate the company has over $14M cash on its balance sheet. We are maintaining our Buy rating."

Acceleron Equity Research (10/1/14)
"We initiate coverage of CEl-SCI Corporation with a Buy rating. . .the company is conducting the world's largest Phase 3 trial for the treatment of head-and-neck cancer, a $6B market. . .CEL-SCI has a manufacturing facility ready for $3B in production."

Edward White, Laidlaw & Company (9/24/14)
"The first volunteer patient has been enrolled and administered Multikine (leukocyte interleukin injection) in CEL-SCI Corporation's Phase 1 trial evaluating perianal wart immunotherapy in HIV/HPV coinfected men and women at the San Diego Naval Medical Center. . .Multikine is also being studied in an ongoing Phase 3 trial for head-and-neck cancer and the company is exploring the treatment of cervical dysplasia in HIV/HPV coinfected women. All three indications represent critical unmet medical needs and we believe any success in treating these diseases with Multikine could translate into significant market opportunities."

Edward White, Laidlaw & Company (8/4/14)
"CEL-SCI Corporation announced that its Phase 3 trial of Multikine for the treatment of head-and-neck cancer has reached 232 patients enrolled. The trial is now 26.4% enrolled and on target to reach 880 patients by the end of 2015. . .during the month of July, four countries approved patient enrollment in the company's Phase 3 trial including Austria, Sri Lanka, Turkey and France."

Edward White, Laidlaw & Company (4/28/14)
"CEL-SCI Corporation announced the closing of a successful $10M secondary offering, as well as the addition of two new U.S. clinical sites in April. . .we are maintaining our Buy rating."

Experts Commenting on This Company


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
CEL-SCI Corporation Content